Protocol AI launch event
Risklick, a spin-off from the University of Bern, today launched its latest product, Protocol AI. Protocol AI is the first software of its kind and marks a turning point in the pharmaceutical industry. It uses artificial intelligence to accelerate the development of clinical trials, reduce costs and increase safety standards. This innovative technology has the potential to revolutionize clinical trials and provide millions of patients worldwide with faster access to life-saving therapies.
In today’s world, developing new therapies typically requires an average of ten years, with costs soaring up to two billion for companies. The most time-consuming and costly aspect of this process is the development and execution of clinical trials. Clinical trials are mandatory processes required for a new treatment to be validated before its commercialization. They are extremely long and complex, often resulting in significant and costly delays or failures. These challenges directly impact both the cost and availability of new treatments for patients, as well as the probability of bringing them to market.
Clinical trials are conducted based on massive and complex protocols developed by experts, which describe all practical modalities of conducting the trial. These documents require approval from regulatory authorities. Developing a protocol demands an average of 12 months of intensive work, where the slightest error can lead to disastrous consequences for the clinical trial.
AI-based software gives patients faster access to therapies
To address these challenges, the spin-off from the University of Bern Risklick has developed Protocol AI. "We have created a pioneering solution that reduces the development time and costs of clinical trials by up to 35%, making it easier for patients to access therapies. Our innovative technology has the potential to improve the lives of millions of patients worldwide," says Poorya Amini, co-founder and CEO of Risklick.
Protocol AI is the first groundbreaking software of its kind employing artificial intelligence to analyze existing clinical data, optimizing their selection and integration through Natural Language Processing (NLP). By extension, Protocol AI facilitates evidence-based decision making and automatic drafting of clinical trial protocols within minutes, utilizing cutting-edge technology based on Large Language Models (LLM) and Machine Learning (ML).
Protocol AI allows experts to drastically reduce the development time of protocols while ensuring the quality, as well as increasing the chances of success of the clinical trial. The AI based tool accelerates and simplifies the development of new treatments, paving the way for medical innovation. Protocol AI promises to revolutionize the field of clinical trials and ultimately improve the lives of millions of patients worldwide through faster access to therapies and medicines.
With Debiopharm, a leading biotechnology company in French-speaking Switzerland, and Integrated Scientific Services, ISS AG, a Swiss clinical research company with expertise in medical devices, digital medicine and IVD, Risklick has already attracted major players from both the pharmaceutical and medical device industries as partners. They see Protocol AI as the ideal solution to the challenges of developing new therapies.
"Our investment in Risklick is a strategic enhancement to our R&D, Clinical Operations, and Regulatory Affairs workflows. Through Protocol AI, we not only accelerate the delivery of innovative treatments but also ensure more efficient trial designs and robust compliance, addressing internal challenges with cutting-edge solutions that benefit our collaborators and patients globally," says Cédric Odje, Investment Associate at Debiopharm.
"Our interest in partnering with Risklick and their product Protocol AI is to gain access to a unique solution that improves quality by systematically and profoundly bringing together all relevant sources of information and automatically track changes throughout the protocol. Protocol AI will improve the design of clinical investigations and thus support the generation of accurate therapeutic data related to medical devices, digital medicines and IVDs," adds Michel Weber, Division Leader Clinical Services at ISS AG.
Protocol AI's technological innovation is also valued by Advanced Clinical, a clinical research organization with decades of experience. Paul Miller, Vice President Commercial Strategy at Advanced Clinical: "Protocol AI offers a unique solution in minimizing AI distortions through precise queries and extracting validated data from diverse registries. This transformative capability can revolutionize clinical trial design and enhance industry access to accurate therapeutic data."
Further information:
Oppenheim & Partner GmbH
David Oppenheim
Stockerstrasse 32
CH-8002
Zürich
Tel: 044 515 65 00
E-Mail: do@oppenheim-partner.ch
About Risklick AG
Risklick is a spin-off of the University of Bern and aims to empower biopharmaceutical and medical device companies to enhance trial success rates and accelerate the delivery of new treatments to patients. The multidisciplinary team comprises data scientists, medical and clinical experts, and software developers, united by a singular vision: revolutionizing clinical trial protocols through AI technology to render trials faster, more cost-effective, and safer for the benefit of all.